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Abstract
Background: Inter-observer variability in stroke aetiological classification may have an effect on trial power
and estimation of treatment effect. We modelled the effect of misclassification on required sample size in a
hypothetical cardioembolic (CE) stroke trial.
Methods: We performed a systematic review to quantify the reliability (inter-observer variability) of various
stroke aetiological classification systems. We then modelled the effect of this misclassification in a hypothetical
trial of anticoagulant in CE stroke contaminated by patients with non-cardioembolic (non-CE) stroke aetiology.
Rates of misclassification were based on the summary reliability estimates from our systematic review. We
randomly sampled data from previous acute trials in CE and non-CE participants, using the Virtual
International Stroke Trials Archive. We used bootstrapping to model the effect of varying misclassification rates
on sample size required to detect a between-group treatment effect across 5000 permutations. We described
outcomes in terms of survival and stroke recurrence censored at 90 days.
Results: From 4655 titles, we found 14 articles describing three stroke classification systems. The inter-observer
reliability of the classification systems varied from ‘fair’ to ‘very good’ and suggested misclassification rates of 5%
and 20% for our modelling. The hypothetical trial, with 80% power and alpha 0.05, was able to show a difference
in survival between anticoagulant and antiplatelet in CE with a sample size of 198 in both trial arms.
Contamination of both arms with 5% misclassified participants inflated the required sample size to 237 and with 20%
misclassification inflated the required sample size to 352, for equivalent trial power. For an outcome of stroke recurrence
using the same data, base-case estimated sample size for 80% power and alpha 0.05 was n = 502 in each arm, increasing
to 605 at 5% contamination and 973 at 20% contamination.
Conclusions: Stroke aetiological classification systems suffer from inter-observer variability, and the resulting misclassification
may limit trial power.
Trial registration: Protocol available at reviewregistry540.
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Background
Stroke is a syndrome with heterogeneous aetiologies.
Grouping these aetiologies together has been effective
when developing acute interventions such as intravenous
thrombolysis, but improved access to imaging, rhythm
monitoring and biomarkers may support a more indivi-
dualised approach to treatment and research. We in-
creasingly acknowledge the relevance of aetiology as a
determinant of prognosis, as a risk factor for recurrence
and as a potential treatment effect moderator.
Various classification systems have been developed to de-
fine stroke aetiology using clinical features and the results
of ancillary investigations. These aetiological classification
tools attempt to categorise stroke, and the subtypes usually
include cardioembolism, large vessel atheroma and small
vessel disease. Robust classification of aetiology is essential
to guide treatment decisions when the optimal pharmaco-
logical treatment differs between aetiological groups. This
situation is seen with prevention of cardioembolic (CE) ver-
sus large vessel stroke, where the differing pathologies
require differing treatment strategies.
The reliability of a classification tool is a measure of the
degree to which results are reproducible when repeated
observations are made, either by the same physician on re-
peated assessments (intra-observer reliability) or between
physicians (inter-observer reliability). Several factors may
impair classification reliability, including inherent proper-
ties of the classification system itself (such as its complex-
ity), properties of the patient population (such as the
spectrum of disease aetiology), the quality and complete-
ness of ancillary data and the expertise of the physicians
using the classification algorithm.
Impaired reliability, regardless of cause, will result in mis-
classification error. This misclassification is problematic for
a number of reasons. It will lead to potentially biased esti-
mates of the prevalence of disease aetiologies and misdir-
ected treatment decisions. Misclassification error may
compromise the statistical power and efficiency of research
studies, inflating their costs and reducing sensitivity. Finally,
misclassification may undermine the estimate of effect size
and reduce apparent efficacy and cost effectiveness [1, 2].
All of these issues are particularly pertinent to the
emerging literature on embolic stroke of undetermined
source (ESUS) [3, 4]. Ongoing and completed large trials
in this area were based on a trial entry classification
paradigm where patients with atrial fibrillation (AF) or
ESUS receive anticoagulation and patients with other,
non-cardioembolic (non-CE) aetiologies receive anti-
platelet treatment. Baseline misclassification of stroke
subtype and subsequent misallocation to treatment arms
could compromise the power of these trials to demon-
strate utility. For example, if a patient with an arterial
atheromatous cause of stroke is erroneously recruited
into an ESUS treatment arm, they will not benefit from
the treatment given, and this will dilute the power to see
a treatment effect.
We designed a programme of work to model the po-
tential effect of aetiological misclassification on sample
size in a hypothetical trial of anticoagulant in CE stroke.
We first describe the reliability (inter-observer variabil-
ity) of stroke classification systems and then model the
effect of this misclassification on sample size required to
show the effect of chosen treatments in terms of survival
and stroke recurrence.
Methods
We used an iterative approach to our analyses. First, we
performed a systematic review and meta-analysis to
quantify potential misclassification rates across different
stroke classification systems. We then performed a scop-
ing analysis, using aggregate data from published trials
to estimate the potential effect of misclassification.
Finally, we used individual patient-level data to model
the impact of misclassification on a hypothetical trial.
Systematic review
We followed, where appropriate, Preferred Reporting
Items for Systematic Review and Meta-Analyses
(PRISMA) best practice guidance for design, conduct
and reporting of our systematic review. We worked ac-
cording to a pre-defined protocol (Research Registry
Unique Identifying Number reviewregistry540, accessible
on URL https://www.researchregistry.com/). Our pri-
mary aim for the systematic review was to describe the
inter-observer reliability of stroke classification systems.
The metric of interest was reliability of the classification
tool, i.e. agreement between observers. We did not
pre-define the classification scales of interest.
We devised a sensitive search strategy using validated
search terms across multidisciplinary electronic data-
bases, from database inception to December 2018 inclu-
sive (Additional file 1: Table S1). We used citation
searching (backwards searching) and assessed all articles
that had cited the index article (forward searching).
There were no restrictions relating to date of publica-
tion, the number of participants or assessors. Only
papers published in peer-reviewed, English language
scientific journals were considered.
Title and abstracts generated from the electronic data-
base searches were screened for relevance, irrelevant ti-
tles and abstracts were excluded and full-text articles
were inspected to determine eligibility. Data from stud-
ies meeting our inclusion criteria were extracted to a
proforma. All aspects of the title searching, assessment
and data extraction were performed by two independent
researchers. Decisions were made by consensus with re-
course to a third arbitrator as necessary. No authors
were contacted for the study.
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We assessed risk of bias using Guidelines for Report-
ing Reliability and Agreement Studies (GRRAS) [5]. The
main characteristics analysed were stroke classification
system, stroke population, assessor population, sample
size calculation, sampling methods, blinding and report-
ing of reliability with a corresponding measure of
uncertainty.
We described inter-observer reliability using the
kappa (κ) statistic, using standard definitions of
poor (κ = 0.00–0.20), fair (κ = 0.21–0.40), moderate
(κ = 0.41–0.60), good (κ = 0.61–0.80) and very good
(κ = 0.81–1.00) reliability [6, 7]. We described the
reliability of stroke classification systems and, where
data were available, the reliability of classification
into CE and non-CE aetiologies.
We used the summary data from the systematic
reviews to inform estimates of potential rates of mis-
classification in a trial that recruited based on stroke
aetiology. We used ‘best case’ and ‘worst case’ reliabil-
ity estimates from the systematic review. There is no
agreed approach for converting kappa values (our
summary agreement metric from meta-analysis) to a
measure of percentage agreement/disagreement (the
measure needed for our modelling exercise). We used
a conversion that has been previously described [8].
We opted for cautious estimates of misclassification
(disagreement) based on the conversion (5% and
20%). We ensured that these values were broadly in
keeping with the data presented in papers that
describe reliability in terms of percentage agreement
as well as kappa.
Effect of stroke classification on trial sample size:
aggregate analyses
We used our summary estimates of misclassification to
inform a series of statistical models. As an initial scoping
exercise we created a hypothetical study of anticoagulant
versus antiplatelet in CE stroke. We used survival out-
comes data from historical stroke trials that included the
use of anticoagulant and antiplatelet treatment in CE
and non-CE stroke, to give proportional survival in each
[9, 10]. We then replaced a proportion of the CE
patients with non-CE patients in each treatment arm.
We used the Pearson chi-square test for proportion dif-
ference, first assuming perfect classification rates and
then factoring in differing rates of misclassification. For
a given rate of misclassification, we substituted that pro-
portion of non-CE stroke patients into the CE treatment
arm and vice versa (Fig. 1).
Effect of stroke classification on trial sample size:
individual patient-level analyses
We then explored the effect of misclassification on a
hypothetical trial involving patients with CE stroke using
individual patient-level data. We used data from the Vir-
tual International Stroke Trials Archive (VISTA), http://
www.virtualtrialsarchives.org/vista/, as the base-case data
to inform our models. VISTA is a not-for-profit reposi-
tory for stroke trial data, containing study quality, anon-
ymised, individual patient-level data on thousands of
participants [11, 12]. These data have been used to
investigate novel hypotheses, including analyses of stroke
assessment scale properties [13, 14].
Fig. 1 Effect of stroke classification on trial sample size: aggregate analyses. VISTA Virtual International Stroke Trials Archive, CE cardioembolic
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We tested a hypothetical misclassification scenario; a
trial that assesses the efficacy of an oral anticoagulant
versus antiplatelet in patients with CE stroke contami-
nated by patients with non-CE stroke (aetiological
misclassification).
From VISTA, we selected populations of CE stroke
treated with anticoagulant or antiplatelet agent, and
populations of non-CE stroke treated with anticoagulant
or antiplatelet. We assumed that patients with known
AF and neither large nor small vessel disease were CE.
We assumed that patients with no AF and proven large
or small vessel disease aetiology of stroke were non-CE.
We calculated an initial sample size for outcomes of
death and stroke recurrence using aggregate VISTA data
from CE-anticoagulant and CE-antiplatelet groups.
We then used bootstrapping simulations with random
repetition sampling to create models to our specified
sample size, n = 7000, using the RAND function in
Matrix Laboratory (MATLAB) software. In the hypo-
thetical ‘treatment’ arm, we randomly selected the
relevant number of correctly classified patients from the
CE cohort treated with anticoagulation and then ran-
domly selected the corresponding number of incorrectly
classified patients from the non-CE cohort treated with
anticoagulant. We created a ‘control’ arm using the same
process, sampling from CE treated with antiplatelet and
contaminating with non-CE treated with antiplatelet.
We summarised outcomes across 5000 permutations.
All analyses were performed using MATLAB Statistics
and Machine Learning Toolbox R2014a (© 1994–2014
The MathWorks, Inc., Natick, MA, USA).
Results
Systematic review
From 4655 titles, we found 14 titles that met the inclu-
sion criteria [15–28] (PRISMA diagram, Additional file
1: Figure S1). The included articles described principally
three stroke classification systems:
1. The automated Causative Classification of Stroke
System (CCS), (n = 4 papers) [17, 26–28]
2. The Trial of Org 10172 in Acute Stroke Treatment
(TOAST) algorithm, (n = 10 papers) [15–24]
3. ASCO system (A for atherosclerosis, S for small
vessel disease, C for cardiac source and O for other
cause, n = 4 papers) [23–26]
Four papers described the reliability of more than one
stroke classification system [17, 23, 24, 26]. Four articles
were suitable to perform a meta-analysis for ’classic’
TOAST [18–21] and four for CCS [17, 26–28] (Table 1).
The assessment of quality and risk of bias are described
in Additional file 1: Table S2. Included papers were
assessed as low risk of basis for most items except
calculation of sample size (not described in 11/14
included papers), blinding of assessors (not described
in 9/14 included papers) and quantifying error in reli-
ability estimates (not described in 8/14 papers).
We were able to describe reliability for classification
scales in general and at the level of individual aeti-
ology. For the different TOAST classification systems,
study-level inter-observer reliability varied from ‘fair’
to ‘very good’ (Table 2). Across the eight studies where
data were suitable for pooled analysis, overall kappa
was moderate (κ = 0.53; 95% confidence interval [CI]
0.49–0.56). For the ’classic’ version of TOAST, pooled
reliability was also moderate (κ = 0.55; 95% CI 0.51–
0.59) (Additional file 1: Figures S2 and S3).
For the different subtypes of CCS classifications,
study-level inter-observer reliability ranged from ‘good’ to
‘very good’. The inter-observer reliability of different sub-
types of CCS suggested that 5 subtype CSS and 8 subtype
CCS had very good overall reliability and 16 subtype CCS
had good overall reliability (Table 2). Overall reliability for 5
major CCS subtype was good (κ = 0.81; 95% CI 0.80–0.83)
(Table 2 and Additional file 1: Figures S4 and S5).
In the case of ASCO, inter-observer variability was de-
scribed according to each potential phenotype and var-
ied from perfect (κ = 1) for the ’C’ (cardiac) phenotype to
good (κ = 0.66) for the ’O’ (other) phenotype (Table 2).
Based on these summary reliability measures, we esti-
mated proportional misclassification extremes at 5% and
20%, representing the approximate misclassification that
may be seen with the most favourable (seen with CCS
and ASCO systems) and the least favourable (TOAST)
reliability estimates.
Effect of stroke classification on trial sample size:
aggregate analyses
In our initial scoping analyses, using aggregate data from
historical trials of anticoagulant in CE and non-CE, we
started with a zero misclassification, base-case scenario
trial of n = 392 to detect an outcome difference in treat-
ment effect in terms of survival (power = 0.8, alpha
0.05). With a misclassification of 5% the required sample
size to demonstrate the same effect was n = 444 (13% in-
crease). With a misclassification of 20% the required
sample size to demonstrate the same effect was n = 663
(69% increase). Detailed analysis results are included in
Additional file 1: Supplemental Results.
Effect of stroke classification on trial sample size:
individual patient-level analyses
We obtained data for 2066 patients with acute ischaemic
stroke from VISTA, of whom 514 had CE on baseline
assessment (n = 207, 40% were on antiplatelet, the re-
mainder anticoagulant) and 1545 patients with non-CE
(n = 1171, 76% were on antiplatelet treatment, the
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remainder anticoagulant). The baseline characteristics of
these patients are shown in Additional file 1: Table S3.
For an outcome of death at first follow-up, based on pro-
portions seen in the aggregate data, a base-case estimate was
of a required sample size of n= 198 for both arms of the trial
to detect a between-group difference (power = 0.8, alpha
0.05). The required sample size to demonstrate a statistically
significant treatment effect increased to n= 237 in each arm
(20% increase) at 5% misclassification and n= 352 (78% in-
crease) at 20% misclassification. For an outcome of stroke re-
currence using these same data, the base-case estimate
sample size was n= 502, increasing to 605 (21% increase) at
5% contamination and 973 (94% increase) at 20% contamin-
ation for each arm of the trial (Table 3).
A 20% contamination of patients with non-CE stroke
in a hypothetical trial of anticoagulant versus antiplatelet
treatment in patients with CE stroke would under-
estimate the effect of anticoagulant treatment by at
least 10% for the outcome of death and 15% for the
outcome of recurrent stroke, compared to a trial
without any contamination. (See Additional file 1:
Supplemental Results.)
Discussion
Our analyses have confirmed that even advanced classifi-
cation systems for stroke aetiology harbour residual
inter-observer variability of at least 5% and potentially
much greater. Based on this variability in classification,
we have shown that the resulting misclassification con-
tributes a sample size penalty of at least 20% and poten-
tial incorrect estimation of the treatment effect size by
at least 10%.
Table 1 Characteristics of included studies
Study Subject
no.
Assessors Assessor
no.
Country Stroke
classification
Single
site
Inter-rater reliability studies
Arsava et al.,
2010 [27]
50 Various physiciansa 15 Internationald CCS No
Ay et al.,
2005 [17]
50 Neurologists 2 USA CCS/TOAST No
Ay et al.,
2007 [28]
50 Neurologists 5 USA CCS No
Chen et al.,
2013 [25]
419 Stroke neurologists 2 China ASCO Yes
Fure et al.,
2005 [16]
38 Junior registrars,
experienced physicians
4 Norway TOAST Yes
Goldstein et al.,
2001 [19]
14 Neurologists, internists 4 USA TOAST computerised
algorithm/ TOAST
No
Gordon et al.,
1993 [22]
18 Neurologists 24 USA TOAST Yes
Han et al.,
2007 [15]
200 Neurologists 3 Korea Han et al., 2007/TOAST Yes
Marnane et al., 2010 [26] 381 Physiciansb U Ireland ASCO/CCS Yes
Meschia et al., 2006 [20] 30 Neurologists 6 USA TOAST No
Nam et al.,
2012 [21]
70 Residents,
stroke experts
7 Korea iTOAST/
TOAST
Yes
Selvarajah et al.,
2009 [18]
90 Various stroke
physiciansc
4 UK TOAST Yes
Wolf et al.,
2012 [23]
103 Stroke physician 2 Germany ASCO/
TOAST
Yes
Intra-rater reliability studies
Cotter et al.,
2011 [24]
106 U U UK ASCO/
TOAST
Yes
All studies were retrospective reviews of clinical materials
U unknown, CCS Causative Classification of Stroke System, TOAST Trial of Org 10172 in Acute Stroke Treatment, ASCO atherosclerosis, small vessel disease,
cardiac source
aIncluded stroke neurologists, clinical neuroscientist, stroke fellowship, trained emergency physician, neurology resident
bIncluded trained stroke physician, nonstroke specialist
cIncluded senior lecturer and research fellow in stroke medicine, clinical consultant neurologist, senior house officer in clinical neurology
dIncluded USA, Italy, Spain, Germany, Austria, Sweden, UK, Nigeria
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It seems plausible that stroke trials targeted at a par-
ticular aetiological subgroup may have been underpow-
ered to demonstrate a treatment effect. To take a
high-profile example, the New Approach riVaroxaban
Inhibition of Factor Xa in a Global trial versus Aspirin
to prevenT Embolism in Embolic Stroke of Undeter-
mined Source (NAVIGATE-ESUS) study was terminated
early because of futility and excess bleeding on rivaroxa-
ban [4]. One can speculate whether this neutral result
was at least partly due to the study being underpowered
as a result of baseline misclassification.
Our results align with previous research looking at
the effect of misclassification of treatment outcomes
in stroke trials [1]. The modified Rankin Scale (mRS)
is the most commonly used outcome measure in
stroke research [29]. Typically, mRS assessment is
based on a clinician’s rating of a patient interview,
and inter-observer variability is common [30].
Meta-analysis suggests that mRS assessments have an
overall reliability of κ = 0.62 (weighted κ = 0.9) [30],
but this may be less (κ = 0.25) in multicentre studies
[31]. However, increasing the reliability of the mRS
assessments by central adjudication (including across
international centres) has been shown to significantly
reduce the required trial sample size and to increase
trial power [1]. Given the substantial and increasing
per patient cost of randomisation into a clinical trial,
funders, trialists and industry have been keen to limit
the potential effect of misclassification on required
sample size. Training in mRS assessment is now
mandatory for many trials, and several contemporary
international stroke trials are using a system of cen-
tral expert adjudication of mRS assessments [32–35].
Table 2 Inter-observer reliability of different types of stroke
classification systems
Study Classification
system
κ 95% CI
TOAST classification system
Ay et al., 2005
[17] (n = 50)
TOAST 0.78 0.64–
0.92
Fure et al., 2005
[16] (n = 38)
TOAST 0.30 *
Goldstein et al., 2001a
[19] (n = 14)
TOAST
(11 categories)
0.29 0.21–
0.37
TOAST 0.42 0.32–
0.53
Goldstein et al., 2001b
[19] (n = 20)
TOAST
computerised
algorithm
0.68 0.44–
0.91
Gordon et al., 1993
[22] (n = 18)
TOAST 0.64 *
Han et al., 2007
[15] (n = 200)
TOAST 0.78 *
Meschia et al., 2006
[20] (n = 30)
TOAST 0.54 0.48–
0.60
Nam et al., 2012
[21] (n = 70)
iTOAST 0.79 0.71–
0.87
TOAST 0.69 0.60–
0.78
Selvarajah et al., 2009
[18] (n = 90)
TOAST 0.42 0.32–
0.52**
Wolf et al., 2012
[23] (n = 103)
TOAST 0.95 *
CCS
Arsava et al., 2010
[27] (n = 50)
CCS: 5 subtype 0.80 0.78–
0.81
8 subtype 0.79 0.77–
0.80
16 subtype 0.70 0.69–
0.71
Ay et al., 2005
[17] (n = 50)
5 subtype 0.86 0.76–
0.96
Ay et al., 2007
[28] (n = 50)
5 subtype 0.86 0.81–
0.91
8 subtype 0.85 0.80–
0.89
16 subtype 0.80 0.76–
0.83
Marnane et al., 2010
[26] (n = 381)
5 subtype 0.64 0.44–
0.82**
ASCO classification system
Chen et al., 2013
[25] (n = 419)
Phenotype: A 0.79 0.74–
0.83
S 0.80 0.75–
0.85
C 0.87 0.83–
0.91
O 0.86 0.78–
0.94
Table 2 Inter-observer reliability of different types of stroke
classification systems (Continued)
Study Classification
system
κ 95% CI
Marnane et al., 2010
[26] (n = 381)
A 0.79 *
S 0.48 *
C 0.88 *
O 0.66 *
Wolf et al., 2012
[23] (n = 103)
A 0.95 *
S 0.95 *
C 1.00 *
O 0.92 *
Other classification system
Han et al., 2007
[15] (n = 200)
Han et al. (2007)
classification
0.82 *
CI confidence interval, TOAST Trial of Org 10172 in Acute Stroke Treatment,
CCS Causative Classification of Stroke System, ASCO atherosclerosis, small
vessel disease, cardiac source
*Unknown 95% CI
**Estimates provided by author
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Comparable approaches could be employed to limit
aetiological misclassification, with the anticipation of
greater trial efficiency. There are many other aspects of
trials within stroke and in other disease areas where mis-
classification could compromise power. More research
around the properties of assessment tools could be useful
to help us understand the potential impact on study re-
sults. Research in stroke suggests that poor reliability is
not inherent and some assessment tools have greater reli-
ability than others [36].
Strengths and limitations of the study
We present a novel analysis on an increasingly pertinent
methodological issue in clinical trials. Our estimates of
misclassification are based on a comprehensive review of
the literature following best practice in systematic review
and meta-analysis. Our modelling was based on individ-
ual patient-level data from completed clinical trials.
There are limitations to this analysis. Our misclassifi-
cation modelling analysis makes a number of assump-
tions. For example, we assume that the historical event
data are still relevant to contemporary patients with
acute stroke. We also assume ‘perfect’ aetiological clas-
sification within the VISTA data that inform our mod-
elling. Converting kappa values from our meta-analyses
to rates of misclassification comes with certain caveats.
We used an accepted ‘rule of thumb’ [8], but this con-
version is imperfect. Based on these criteria, TOAST
agreement could be anything from 30 to 80%. We
opted for cautious estimates of misclassification (dis-
agreement), although arguably our misclassification
rates could have been much higher. In all our analyses,
we assume that the misclassification described and
modelled above affects the cardioembolic (CE) and the
non-CE groups. Finally, it is possible that misclassifica-
tion may affect one treatment arm more than the other.
These limitations are all likely to underestimate any
deleterious effects of misclassification on sample size,
and so we believe our message remains valid.
Our analysis modelled outcomes of survival and stroke
recurrence, as these are the endpoints most commonly
described in anticoagulant trials. We acknowledged that
other outcomes may also be relevant and subject to mis-
classification effects, for example functional recovery or
non-fatal adverse events.
We use anticoagulation in the context of AF as a
model, as these were the data available. It would be
unwise to directly extrapolate these data to ESUS tri-
als. The natural history, effect sizes and adverse event
risks will differ between ESUS and the proven AF
used in our models, but our analysis is designed to
be illustrative of the potential statistical effect rather
than a direct comment on ESUS trials.
Implications for future practice and research
The stroke classification systems we studied are imper-
fect, but defining an underlying aetiology for stroke
may still be important for personalised stroke treatment
and research. Our findings should not deter clinicians
and trialists from trying to classify patients; rather, we
believe that strategies to improve the reliability of
aetiological classification are needed. Some may argue
that the move towards precision in therapeutics is less
relevant in stroke, as recurrence is not unique to the
aetiology of the index event. In the secondary stroke
prevention subgroups of the non-vitamin K antagonist
anticoagulant trials, 50% of the patients in addition to
AF had atherosclerosis in terms of stable coronary ar-
tery disease, peripheral artery disease or plaques in the
carotid arteries [37–39]. In addition, we know from the
long-term electrocardiographic (ECG) monitoring trials
that 10–15% of patients per year develop silent parox-
ysmal AF [40, 41]. However, trials of aetiologically spe-
cific intervention continue, and it seems sensible to
minimise and account for the effect of any aetiological
misclassification. Perhaps future trials should have the
aetiological classification done by independent physi-
cians at study entry, halfway through the study and at
the end of the study.
Previous work on mRS assessments showed that
introduction of training, structured assessment and
consensus review can reduce misclassification in out-
come adjudication [1]. It seems plausible that the same
may be true for aetiological classification. Further work
to quantify misclassification in contemporary stroke
practice is needed. Our work offers some rough esti-
mates of misclassification effect that stroke trialists
could factor into the design of trials and estimates of
required sample size.
Conclusions
Aetiological classification systems are associated with
inter-observer variability. The resulting misclassification
of stroke aetiology may reduce trial power to adequately
identify effective stroke prevention therapy, reduce the ef-
fect size and increase associated trial costs.
Table 3 Effect of misclassification levels on the required sample
size in a hypothetical trial of anticoagulant versus antiplatelet in
patients with cardioembolic stroke to demonstrate statistically
significant result for the relevant outcomes, using N = 5000
permutations
Stroke aetiology
misclassification level
Death Recurrent stroke
0% 198 502
5% 237 (20% increase) 605 (21% increase)
20% 352 (78% increase) 973 (94% increase)
Sample sizes calculated with power = 0.8, alpha = 0.05
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